Serum tsRNA marker related to glioma diagnosis and application thereof

By using serum tsRNA as a biomarker in gliomas, a diagnostic kit was developed, which solved the problem of insufficient diagnostic sensitivity and specificity of gliomas in the prior art, and achieved efficient and accurate diagnosis of gliomas. Clinical treatment provides new support.

CN118932058APending Publication Date: 2024-11-12ZHEJIANG CANCER HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411109626.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There is a lack of effective biomarkers in the prior art for early diagnosis of gliomas, and traditional protein detection methods have problems with insufficient sensitivity and specificity.

Method used

Using tsRNAs with specific sequences in serum (such as tRF-Thr-CGT-009 and tRF-Gly-CCC-015) as biomarkers, we develop corresponding diagnostic kits, and use primer pairs to detect the use of primer pairs and internal reference primer pairs to achieve Auxiliary diagnosis and monitoring of glioma.

Benefits of technology

Improve the diagnostic sensitivity and specificity of glioma, provide a new minimally invasive and easy-to-detection method, provides new ideas for the early diagnosis and clinical treatment of glioma, and provides in-depth research and potential therapeutic targets. Laid the foundation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932058A_ABST
    Figure CN118932058A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, discloses a serum tsRNA marker related to glioma diagnosis and application of the serum tsRNA marker, and identifies a serum tsRNA molecule capable of being used for distinguishing the difference between a glioma patient and a normal person by screening a serum sample of the glioma patient. The serum tsRNA marker is one of tRF-Thr-CGT-009 and tRF-Gly-CCC-015 or a combination of the tRF-Thr-CGT-009 and the tRF-Gly-CCC-015 and the tsRNA marker is one of the The serum tsRNA screened by the invention has high test specificity and sensitivity on glioma patients, and can greatly improve the accuracy of glioma diagnosis. The marker can be applied to preparation of a diagnostic kit and is beneficial to early diagnosis of glioma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of molecular biotechnology and relates to a serum tsRNA marker related to glioma diagnosis and application thereof. Background Art

[0002] Glioblastoma multiforme (GBM) is a common malignant tumor in the central nervous system (CNS) and one of the diseases that seriously threatens human health. Glioma cells have the characteristics of rapid proliferation, migration and invasion, as well as the ability to stimulate angiogenesis, so gliomas grow in an expansive and invasive manner and tend to develop to a higher grade. According to the standards of the World Health Organization, brain gliomas can be divided into: grades I to IV. Low-grade gliomas (LGGs) are WHO grade I and II gliomas, and high-grade gliomas are WHO grade III and IV gliomas. The current standard treatment for glioma patients is surgical resection, followed by radiotherapy and chemotherapy. As the highest grade of glioma, GBM accounts for more than half of all gliomas, most of which are incurable. Therefore, screening sensitive and effective biomarkers and diagnosing and detecting gliomas at an early stage is an effective way to improve the treatment effect of glioma patients and prolong their survival.

[0003] Functional non-coding small RNAs have been a hot topic in recent years in tumor and molecular biology research. With the development and application of RNA high-throughput sequencing technology, people have discovered and identified a variety of new functional non-coding small RNAs, including tRNA-derived small RNAs (tsRNAs) named in recent years. tsRNA is about 18-40nt long and is derived from tRNA precursors or mature bodies. Recent studies have found that tsRNA is involved in regulating a variety of physiological and pathological functions, including stress, gene silencing, translation regulation, RNA reverse transcription, mRNA stability and epigenetics. Studies have found that tsRNA is closely related to the occurrence and development of tumors. It has been reported that tsRNA is abnormally expressed in lung cancer, breast cancer, liver cancer, pancreatic cancer, acute myeloid leukemia and chronic lymphocytic leukemia, and plays an important role in the occurrence and development of tumors.

[0004] A large number of studies have found that non-coding small RNAs that are stable and spatiotemporally specific in serum can be used as serological markers for the diagnosis of a variety of diseases, and are more specific and effective than traditional specific protein detection. Recent studies have found that tsRNAs can also be stable and abundant in serum, but no relevant studies on serum tsRNA and glioma have been reported. If abnormally expressed serum tsRNAs in glioma can be screened as biomarkers and corresponding diagnostic kits can be developed, there will be broad application prospects for the diagnosis of glioma. Summary of the invention

[0005] The purpose of the present invention is to provide a serum tsRNA marker related to glioma diagnosis, and the use of the serum tsRNA marker in the preparation of a glioma diagnosis kit.

[0006] To achieve the above object, the technical solution of the present invention is as follows:

[0007] In a first aspect, the present invention claims the use of tsRNA as a biomarker in any of the following (a1)-(a4):

[0008] (a1) preparing products for diagnosing or assisting in the diagnosis of glioma;

[0009] (a2) preparing products for screening or assisting in screening of glioma;

[0010] (a3) preparing products for monitoring or assisting in monitoring glioma;

[0011] (a4) preparing a product for distinguishing or assisting in distinguishing glioma patients from healthy subjects;

[0012] The tsRNA is tRF-Thr-CGT-009 or / and tRF-Gly-CCC-015, the nucleotide sequence of the tRF-Thr-CGT-009 is shown in SEQ ID NO: 1; the nucleotide sequence of the tRF-Gly-CCC-015 is shown in SEQ ID NO: 2.

[0013] tRF-Thr-CGT-009:GGCCCTGTAGCTCAG(SEQ ID NO:1)

[0014] tRF-Gly-CCC-015: GCGCCGCTGGTGTA (SEQ ID NO: 2).

[0015] In a second aspect, the present invention claims the use of a substance for detecting tsRNA in any of the following (a1)-(a4):

[0016] (a1) preparing products for diagnosing or assisting in the diagnosis of glioma;

[0017] (a2) preparing products for screening or assisting in screening of glioma;

[0018] (a3) preparing products for monitoring or assisting in monitoring glioma;

[0019] (a4) preparing a product for distinguishing or assisting in distinguishing glioma patients from healthy subjects;

[0020] The tsRNA is tRF-Thr-CGT-009 or / and tRF-Gly-CCC-015, the nucleotide sequence of the tRF-Thr-CGT-009 is shown in SEQ ID NO: 1; the nucleotide sequence of the tRF-Gly-CCC-015 is shown in SEQ ID NO: 2.

[0021] Furthermore, the tsRNA is serum tsRNA.

[0022] Furthermore, the substance includes a primer pair. Furthermore, the primer pair for detecting the tRF-Thr-CGT-009 consists of two single-stranded DNAs shown in SEQ ID NO:3 and SEQ ID NO:4; the primer pair for detecting the tRF-Gly-CCC-015 consists of two single-stranded DNAs shown in SEQ ID NO:5 and SEQ ID NO:6.

[0023] Wherein, the primer sequence used to amplify the tRF-Thr-CGT-009 is:

[0024] F: 5'-GCGCCGGGCCCTGTA-3' (SEQ ID NO: 3)

[0025] R: 5'-AGTGCAGGGTCCGAGGTATT-3' (SEQ ID NO: 4)

[0026] The primer sequence used to amplify the tRF-Gly-CCC-015 is:

[0027] F: 5'-CGCGCGCGGCGCCGCT-3' (SEQ ID NO: 5)

[0028] R: 5'-AGTGCAGGGTCCGAGGTATT-3' (SEQ ID NO: 6).

[0029] Furthermore, the substance also contains an internal reference primer pair for amplifying the internal reference U6; the internal reference primer pair consists of two single-stranded DNAs shown in SEQ ID NO:7 and SEQ ID NO:8.

[0030] The sequence of the internal reference primer used to amplify the internal reference U6 is:

[0031] F: 5'-GCTTCGGCAGCACATATACTAAAAT-3' (SEQ ID NO:7)

[0032] R: 5'-CGCTTCACGAATTTGGCTGTCAT-3' (SEQ ID NO: 8).

[0033] In the third aspect, the present invention claims protection for a group of serum tsRNA markers related to the diagnosis or auxiliary diagnosis of glioma, wherein the serum tsRNA markers are tRF-Thr-CGT-009 and / or tRF-Gly-CCC-015, and the nucleotide sequence of the tRF-Thr-CGT-009 is shown in SEQ ID NO: 1; the nucleotide sequence of the tRF-Gly-CCC-015 is shown in SEQ ID NO: 2.

[0034] In a fourth aspect, the present invention seeks protection for a product for diagnosing or assisting in the diagnosis of glioma, wherein the product comprises a substance for detecting the above-mentioned serum tsRNA marker.

[0035] Furthermore, the product is a kit, and the product includes a primer pair for detecting the tRF-Thr-CGT-009 or / and tRF-Gly-CCC-015, the primer pair for detecting the tRF-Thr-CGT-009 is composed of two single-stranded DNAs shown in SEQ ID NO:3 and SEQ ID NO:4; the primer pair for detecting the tRF-Gly-CCC-015 is composed of two single-stranded DNAs shown in SEQ ID NO:5 and SEQ ID NO:6. Further, the product also contains an internal reference primer pair for amplifying the internal reference U6; the internal reference primer pair is composed of two single-stranded DNAs shown in SEQ ID NO:7 and SEQ ID NO:8.

[0036] Compared with the existing technology, the advantages of the present invention are:

[0037] (1) Unlike traditional protein biomarkers, serum tsRNAs are a new type of biomarker that is highly stable, minimally invasive, easy to detect, and quantitatively accurate. It will greatly improve the sensitivity and specificity of disease diagnosis, help in the auxiliary diagnosis of glioma, and provide a reference for the development of biomarkers for other diseases.

[0038] (2) The present invention systematically studies the role of serum tsRNAs in glioma diagnosis for the first time, revealing its clinical value for glioma screening and diagnosis. Therefore, the present invention obtains glioma serum tsRNAs markers; through the development and application of serum tsRNAs biomarkers and diagnostic kits, the diagnosis of glioma can be made more convenient and easy, which not only lays the foundation for in-depth research on tsRNA in glioma, but also provides new ideas for clinical diagnosis and treatment, and helps to discover new small molecule drug targets with potential therapeutic value.

[0039] (3) The serum tsRNAs kit is a comprehensive and systematic diagnostic and monitoring kit that can be used for the early diagnosis of glioma patients, help reflect the disease status of glioma patients, and provide better support for clinical treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 This is a sequencing heat map of the 30 tsRNAs with the most significant expression differences in the serum of glioma patients and healthy controls.

[0041] Figure 2 The expression levels of the six tsRNAs (tRF-Thr-CGT-009; tRF-Val-CAC-024; tRF-Gly-CCC-015; tRF-Ser-GCT-006, tRF-Leu-TAA-006; tRF-Leu-CAA-003) in the serum of the brain glioma patient group and the healthy control group, respectively.

[0042] Figure 3 The expression levels of two tsRNA (tRF-Thr-CGT-009 and tRF-Gly-CCC-015) markers in the serum of glioma patients and healthy controls.

[0043] Figure 4 ROC plots of the diagnostic effects of two tsRNA markers (tRF-Thr-CGT-009 and tRF-Gly-CCC-015) on glioma patients and healthy controls, respectively.

[0044] Figure 5 ROC plot of the diagnostic effect of the combination of tRF-Thr-CGT-009 and tRF-Gly-CCC-015 on glioma patients and healthy controls. DETAILED DESCRIPTION

[0045] The present invention is further described below in conjunction with the accompanying drawings and embodiments. It should be understood that the following specific embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0046] Example 1

[0047] The researchers first collected peripheral serum samples from glioma patients and healthy people, extracted RNA for tsRNA high-throughput sequencing analysis, and obtained a set of tsRNA markers related to glioma diagnosis through a small sample screening and large sample clinical verification scheme. Based on this, they developed a kit that can be used for the clinical diagnosis of glioma, providing a basis for the screening and early diagnosis of glioma.

[0048] The technical solution to solve the problem of the present invention includes:

[0049] (1) Collect blood samples that meet the standards according to standard operating procedures (SOPs) and systematically collect complete clinical case information.

[0050] (2) Screening and analysis of serum tsRNA differential expression profiles: Glioma patients and healthy controls matched with the glioma patients in age and gender were screened, serum was isolated, and serum tsRNA expression profiles were analyzed by sequencing. Differentially expressed tsRNAs were screened and validated in multiple stages using large samples.

[0051] (3) Quantitative analysis was performed on the differentially expressed serum tsRNA screened previously to identify the serum tsRNA associated with the pathogenesis of glioma.

[0052] (4) Develop a glioma diagnostic kit based on the serum tsRNA screened above.

[0053] Specifically, it includes the following parts:

[0054] (1) Collect patient samples: ① Glioma cases diagnosed by imaging and confirmed by pathology; ② All samples are preoperative, without chemoradiotherapy and neoadjuvant therapy; ③ Healthy controls are normal people with age and gender matching with the patients. The present invention collects serum samples from glioma patients and healthy people for research.

[0055] (2) Serum total RNA was extracted using the Trizol (Invitrogen life technologies) method.

[0056] (3) RNA quality detection: The purity and concentration of RNA were detected by agarose gel electrophoresis and qubit.

[0057] (4) Small RNA high-throughput sequencing:

[0058] ① Recover the total RNA extracted above by PAGE electrophoresis;

[0059] ②tsRNAs are modified by a large number of RNAs, which will interfere with the construction of small RNA seq libraries. Before preparing the library for the total RNA sample, the following treatments were performed: The linker primer (adaptorprime) was enzyme-linked to the 3′ and 5′ ends of the small RNA molecules: All tsRNA library construction and deep sequencing were completed by Aksomics (Shanghai, China). The size selection of sequencing libraries was used for RNA biological type sequencing using an automatic gel cutter. These libraries were rigorously quantitatively analyzed using the Agilent Bioanalyzer 2100. sRNA libraries were constructed according to the Agilent Bioanalyzer 2100. Illumina NextSeq instrument standard small RNA sequencing, sequencing type 50bp single read.

[0060] ③ Perform RT-PCR reaction and then perform sequencing.

[0061] ④ Detect and compare the changes in tsRNA expression in serum samples of glioma patients and healthy normal controls.

[0062] (6) Preparation of glioma tsRNA diagnostic kit

[0063] ① In the early stage, small RNA high-throughput sequencing was used to detect tsRNA with copy differences and expression differences between glioma patients and normal controls, and qRT-PCR technology was used to further detect serum tsRNA with significant differences between glioma patients and healthy controls as an indicator for assisting glioma diagnosis. Finally, serum tsRNA composition diagnostic markers related to glioma (tRF-Thr-CGT-009 and tRF-Gly-CCC-015) were screened.

[0064] ② Primers and external references

[0065] Ⅰ. Reverse transcription primer (RT):

[0066] tRF-Thr-CGT-009 reverse transcription primer:

[0067] 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTGAGC-3'

[0068] (SEQ ID NO:9)

[0069] tRF-Gly-CCC-015 reverse transcription primer:

[0070] 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTACACC-3'

[0071] (SEQ ID NO: 10)

[0072] II. qRT-PCR Primers:

[0073] The primer sequences used to amplify the tRF-Thr-CGT-009 are:

[0074] F: 5'-GCGCCGGGCCCTGTA-3' (SEQ ID NO: 3)

[0075] R: 5'-AGTGCAGGGTCCGAGGTATT-3' (SEQ ID NO: 4)

[0076] The primer sequence used to amplify the tRF-Gly-CCC-015 is:

[0077] F: 5'-CGCGCGCGGCGCCGCT-3' (SEQ ID NO: 5)

[0078] R: 5'-AGTGCAGGGTCCGAGGTATT-3' (SEQ ID NO: 6).

[0079] Ⅲ. Internal reference primer:

[0080] The sequence of the internal reference primer used to amplify the internal reference U6 is:

[0081] F: 5'-GCTTCGGCAGCACATATACTAAAAT-3' (SEQ ID NO:7)

[0082] R: 5'-CGCTTCACGAATTTGGCTGTCAT-3' (SEQ ID NO: 8).

[0083] (7) Data analysis

[0084] All statistical tests were performed using GraphPad Prism v8 (GraphPad Software, Inc, La Jolla, CA, USA). Data are presented as mean ± SEMs. P < 0.05 was considered statistically significant. Normality and equal variance of samples between groups were assessed using the Shapiro-Wilk test and the Brown-Forsythe test, respectively. When normality and equal variance were achieved between sample groups, one-way ANOVA (followed by Bonferroni multiple comparison test), two-way ANOVA (followed by Bonferroni multiple comparison test), or t-test were used.

[0085] The following is a further description of the present invention:

[0086] During the exploration phase, the inventors used small RNA high-throughput sequencing on 20 glioma sera and 20 healthy control sera. Through screening, they found that 243 tsRNAs were significantly increased in glioma serum samples, and 228 tsRNAs were significantly decreased. Figure 1 The 30 tsRNAs with the most significant changes between the glioma group and the healthy group (CPM>20, fold difference>4) are shown.

[0087] Based on the sequencing results, the inventors selected the top six tsRNAs with increased expression in glioma patients for analysis, including: tRF-Thr-CGT-009; tRF-Val-CAC-024; tRF-Gly-CCC-015; tRF-Ser-GCT-006, tRF-Leu-TAA-006; tRF-Leu-CAA-003.

[0088] The above six highly expressed tsRNAs were detected by two analytical methods respectively, and further verified in another 40 glioma patients and 40 healthy controls based on the absolute quantitative method. The results are as follows Figure 2 Among them, the expression of tRF-Thr-CGT-009 and tRF-Gly-CCC-015 was significantly increased in the glioma group.

[0089] Based on the above results, the above two tsRNAs were further tested and verified in the serum of another 108 healthy controls and 100 glioma patients to observe the stability of the results of this study. The results showed that tRF-Thr-CGT-009 and tRF-Gly-CCC-015 were significantly increased in glioma samples. Figure 3 shown.

[0090] Further analysis of the effects of the above two tsRNAs for glioma diagnosis showed that tRF-Thr-CGT-009 and tRF-Gly-CCC-015 had a good diagnostic effect on glioma. Figure 4 shown.

[0091] Further analysis showed that the AUC (Area Under the ROCCurve) of the two tsRNA combinations for glioma diagnosis increased compared with that of a single tsRNA. The results of the combined analysis of the above two tsRNAs showed that the combined diagnosis of tRF-Thr-CGT-009 and tRF-Gly-CCC-015 showed higher sensitivity and specificity. Figure 5 shown.

Claims

1. Use of tsRNA as a biomarker in any of the following (a1)-(a4): (a1) preparing products for diagnosing or assisting in the diagnosis of glioma; (a2) preparing products for screening or assisting in screening of glioma; (a3) preparing products for monitoring or assisting in monitoring glioma; (a4) preparing a product for distinguishing or assisting in distinguishing glioma patients from healthy subjects; The tsRNA is tRF-Thr-CGT-009 or / and tRF-Gly-CCC-015, the nucleotide sequence of the tRF-Thr-CGT-009 is shown in SEQ ID NO: 1; the nucleotide sequence of the tRF-Gly-CCC-015 is shown in SEQ ID NO:

2.

2. Use of a substance for detecting tsRNA in any of the following (a1)-(a4): (a1) preparing products for diagnosing or assisting in the diagnosis of glioma; (a2) preparing products for screening or assisting in screening of glioma; (a3) preparing products for monitoring or assisting in monitoring glioma; (a4) preparing a product for distinguishing or assisting in distinguishing glioma patients from healthy subjects; The tsRNA is tRF-Thr-CGT-009 or / and tRF-Gly-CCC-015, the nucleotide sequence of the tRF-Thr-CGT-009 is shown in SEQ ID NO: 1; the nucleotide sequence of the tRF-Gly-CCC-015 is shown in SEQ ID NO:

2.

3. The use according to claim 1 or 2, characterized in that: The tsRNA is serum tsRNA.

4. The use according to claim 2, characterized in that: The substances include primer pairs.

5. The use according to claim 4, characterized in that: The primer pair used to detect the tRF-Thr-CGT-009 consists of two single-stranded DNAs shown in SEQ ID NO:3 and SEQ ID NO:4; the primer pair used to detect the tRF-Gly-CCC-015 consists of two single-stranded DNAs shown in SEQ ID NO:5 and SEQ ID NO:

6.

6. The use according to claim 4 or 5, characterized in that: The substance also contains an internal reference primer pair for amplifying the internal reference U6; the internal reference primer pair consists of two single-stranded DNAs shown in SEQ ID NO:7 and SEQ ID NO:

8.

7. A group of serum tsRNA markers related to the diagnosis or auxiliary diagnosis of glioma, characterized in that: The serum tsRNA marker is tRF-Thr-CGT-009 or / and tRF-Gly-CCC-015, the nucleotide sequence of the tRF-Thr-CGT-009 is shown in SEQ ID NO:1; the nucleotide sequence of the tRF-Gly-CCC-015 is shown in SEQ ID NO:

2.

8. A product for diagnosing or assisting in the diagnosis of glioma, characterized in that: The product contains a substance for detecting the serum tsRNA marker described in claim 7.

9. The product according to claim 8, characterized in that The product is a kit, which includes a primer pair for detecting the tRF-Thr-CGT-009 and / or tRF-Gly-CCC-015, the primer pair for detecting the tRF-Thr-CGT-009 consists of two single-stranded DNAs shown in SEQ ID NO:3 and SEQ ID NO:4; the primer pair for detecting the tRF-Gly-CCC-015 consists of two single-stranded DNAs shown in SEQ ID NO:5 and SEQ ID NO:

6.

10. The product according to claim 8 or 9, characterized in that The product also contains an internal reference primer pair for amplifying the internal reference U6; the internal reference primer pair consists of two single-stranded DNAs shown in SEQ ID NO:7 and SEQ ID NO:8.